Connect Biopharma Holdings Limited · NASDAQ:CNTB

Connect Biopharma — Technical Presentation (March 2023)

5 slides from Connect Biopharma's technical presentation, March 2023

  1. Slide 1: Rapid and Sustained Improvements with CBP-201 Across All Body Regions

    Rapid and Sustained Improvements with CBP-201 Across All Body Regions: Treatment of Atopic Dermatitis in a Phase 2b, Randomized, Double-blind, Placebo-controlled Trial (CBP-201-WW001) Jonathan I Silverberg1, Malinda Longphre2, Jang Yun2, Zheng Wei2, Chin Lee2, Raúl Collazo2 1The George Washington Un

  2. Slide 2: Change from baseline in EASI total scores at Weeks 2 and 16

    Change from baseline in EASI total scores at Weeks 2 and 16 2 Rapid and sustained improvements were observed in AD signs by body region Head and neck Trunk Week 2 Week 16 Week 2 Week 16 0.0 0.0 EASI total scores LS mean (SE) % change LS mean (SE) % change -20.0 -10.0 -20.0 were weighted for -12.9 -4

  3. Slide 3: Change from baseline in EASI subscores at Week 16

    Change from baseline in EASI subscores at Week 16 3 Improvements were observed in individual AD signs by body region Head and neck Erythema Trunk Erythema 0 0 -20 -20 -40 -40 In these spider diagrams, -60 -60 a corner closer to the center indicates greater -80 -80 Induration/ Induration/ LS mean % r

  4. Slide 4: Patients with ≥50%/75%/90% reductions in EASI total scores at Week 16

    Patients with ≥50%/75%/90% reductions in EASI total scores at Week 16 4 Improvements were observed in EASI response rates by body region Head and neck Trunk 100 100 80 80 * * † % patients % patients 59.6 58.9 † † 60 50.9 † 60 * 45.6 44.6 41.1 40.4 39.3 † 40 35.7 * 40 * 33.3 30.4 26.8 29.8 23.2 19.6

  5. Slide 5: Summary

    Summary 5 • In the primary analysis, CBP-201 was associated with rapid and sustained reductions in EASI total scores through to Summary of LS mean percent reduction in EASI total scores, Week 16, without plateauing1,2 and EASI response rates, at Week 16, by body region • In these post hoc analyses,

Connect Biopharma Holdings — Technical Presentation (March 2023) on 6ix